family with sequence similarity 220 member AGenealiases: ACPIN1 · C7orf70 · SIPAR
Q-omics provides the consensus-scored FAM220A profile across patient tissues and cancer cell-line models. FAM220A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, FAM220A is differentially expressed in 15, with the highest sampling consensus in LUAD. Additionally, FAM220A RNA expression shows 19,644 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, LUAD, and ACC as cancer lineages where FAM220A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM220A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM220A survival associations across molecular data types. FAM220A RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM220A RNA expression–survival associations across cancer types. High FAM220A expression shows unfavorable associations in MESO, KIRP, BLCA and LIHC, but favorable associations in KIRC and ESCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for FAM220A RNA expression.
This table summarizes FAM220A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM220A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM220A shows lower tumor expression in THCA and higher tumor expression in LUAD, HNSC, KIRP, KIRC and COAD. The LUAD box plot shows higher FAM220A RNA expression in tumor versus normal tissue (log2 FC = +1.355, t-test p < 0.001).
This table shows molecular features associated with FAM220A in patient tissues and cancer cell lines. In patient samples, FAM220A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM220A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
